RecruitingPhase 2NCT05283720
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Epcoritamab(drug)
- Enrollment
- 496 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2032
Study locations (30)
- The University of Arizona Cancer Center - North Campus /ID# 242219, Tucson, Arizona, United States
- Yale University School of Medicine /ID# 242089, New Haven, Connecticut, United States
- Christiana Care Health Service /ID# 242301, Newark, Delaware, United States
- Tampa General Hospital /ID# 246748, Tampa, Florida, United States
- Winship Cancer Institute of Emory University /ID# 242153, Atlanta, Georgia, United States
- University of Maryland, Baltimore /ID# 242218, Baltimore, Maryland, United States
- Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
- Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
- Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States
- Novant Health Presbyterian Medical Center /ID# 242148, Charlotte, North Carolina, United States
- East Carolina University - Brody School of Medicine /ID# 242506, Greenville, North Carolina, United States
- Novant Health Forsyth Medical Center /ID# 242198, Winston-Salem, North Carolina, United States
- Thomas Jefferson University Hospital /ID# 242077, Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center /ID# 242106, Philadelphia, Pennsylvania, United States
- Thompson Cancer Survival Ctr /ID# 242150, Knoxville, Tennessee, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05283720 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- ACTIVE NOT RECRUITINGPHASE1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics